AI

OpenAI acquires Orchestra Bio to expand its life sciences AI work

OpenAI has acquired Orchestra Bio, a startup developing AI agents for drug development. OpenAI plans to add the startup’s team and technology to Rosalind, its AI model for life sciences research, and Rosalind Workbench, a tool for planning experiments and analyzing results. The deal brings Orchestra Bio’s technology into OpenAI’s efforts to support pharmaceutical and biopharma research and drug development.

AI-written summary, checked against the cited sources. How summaries work

Primary source

OpenAI acquires Orchestra Bio OpenAI News

What we know

Confirmed by several sources

Reported by one source

  • OpenAI plans to add Orchestra Bio’s team and technology to Rosalind and Rosalind Workbench. — TechCrunch
  • Orchestra Bio builds AI agents to help pharmaceutical companies manage drug development. — Techmeme
  • Orchestra Bio’s technology is intended to support life sciences R&D and help biopharma teams advance drug development. — OpenAI News

Coverage 3 publishers

  1. OpenAI NewsFirst reportPrimary source

    OpenAI acquires Orchestra Bio

    OpenAI is acquiring Orchestra Bio to bring AI-powered operations to life sciences R&D, helping biopharma teams accelerate drug development and advance new treatments.

  2. Techmeme

    OpenAI acquires Orchestra Bio, which builds AI agents for managing drug development, and plans to integrate its tech into OpenAI life sciences suite Rosalind

    OpenAI has acquired Orchestra Bio, a startup building AI agents to help pharmaceutical companies manage drug development, the ChatGPT maker shared exclusively with Axios.

  3. TechCrunch

    OpenAI acquires startup Orchestra Bio⁠ to beef up its biotech business

    OpenAI says it's adding Orchestra's team and technology to work on Rosalind, its AI model for life sciences research, and to its related Rosalind Workbench tool, a harness that aims to help researchers plan experiments and analyze results.

Earliest report first. Articles stay on their publishers’ sites; each link opens the original.